INTENSITY THERAPEUTICS INC (INTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.10+2.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INTS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Reinitiate patient enrollment and site activations in the Phase 3 soft tissue sarcoma study using an FDA-reviewed amended protocol.
Stated as a priority in 2 of last 2 quarters. Enrollment in the Phase 3 INVINCIBLE-3 Study was paused in March 2025 after enrolling 21 patients. Management initiated activities to resume enrollment in limited U.S. sites by Q3 2026. The trajectory shows delivering on the plan to restart enrollment following funding and protocol amendments.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026.”
“Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study by the third quarter of 2026.”
Continue patient treatment and enrollment in the Phase 2 presurgical TNBC study, targeting complete enrollment by end of 2027.
Stated as a priority in 2 of last 2 quarters. Patient treatment restarted in the Phase 2 INVINCIBLE-4 Study in 2026-Q2 after protocol amendments approved in 2026-Q1. Preliminary data show a 71% pathological complete response rate in the INT230-6 cohort. The trajectory is delivering with resumed enrollment and encouraging early efficacy signals.
“Patient treatment restarted in the presurgical triple negative breast cancer Phase 2 INVINCIBLE-4 Study.”
“Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in Q2 2026.”
Extend cash runway with capital raised via ATM facility and manage cash burn to support clinical programs.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents decreased from $10.2 million in 2026-Q1 to $9.5 million in 2026-Q2 despite raising $1.6 million net proceeds under the ATM facility. Management has extended the cash runway to the end of Q1 2027. The trajectory shows ongoing cash management with capital raises supporting clinical activities.
“Raised $1.6 million net proceeds under ATM; cash and cash equivalents of $9.5 million as of June 30, 2026.”
“Established $60 million ATM facility in March 2026; cash and cash equivalents of $10.2 million as of March 31, 2026.”
Expand the at-the-market offering program to enhance financial flexibility.
Focus on managing operating losses as the company continues to report negative operating income.
Over the trailing year it converted 0.67x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.